Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S (MRK) Price & Analysis

5 Followers

MRK Stock Chart & Stats

C$27.63

-C$0.40(-1.43%)

Jul 10, 2026

―

Day’s Range― - ―

52-Week RangeC$23.61 - C$30.21

Previous CloseN/A

VolumeN/A

Average Volume (3M)1.19K

Market Cap

C$437.85B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)5.7

Beta0.87

Next Earnings

Aug 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.35

Shares Outstanding2,469,824,500

10 Day Avg. Volume1,194

30 Day Avg. Volume1,194

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S News

Merck confirms FDA approves Keytruda combos with Padcev

Merck (MRK) announced the U.S. Food and Drug Administration approved KEYTRUDA and KEYTRUDA QLEX, Merck’s anti-PD-1 therapies, each...

23h ago

MRK

Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC

Pfizer (PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration has approved PADCEV, a...

1d ago

MRK

PFE

FDA approves Keytruda combos for certain muscle invasive bladder cancer cases

The Food and Drug Administration announced that it has approved pembrolizumab, or Keytruda, from Merck (MRK), or pembrolizumab...

1d ago

MRK

Redwire appoints Paul Reichert, Niki Werkheiser as SpaceMD advisors

Redwire Corporation (RDW) has appointed Paul Reichert, former Principal Investigator at Merck Research Laboratories (MRK), and Niki Werkheiser,...

3d ago

MRK

RDW

Merck price target raised to $150 from $145 at Wells Fargo

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Merck (MRK) to $150 from $145 and...

3d ago

MRK

Merck price target raised to $150 from $135 at HSBC

HSBC analyst Rajesh Kumar raised the firm’s price target on Merck (MRK) to $150 from $135 and keeps...

5d ago

MRK

Merck terminates Phase 2 Alzheimer’s study

Merck (MRK) has terminated a Phase 2 randomized, placebo-controlled study that was intended to evaluate the efficacy and...

10d ago

MRK

AI Daily: Amazon’s AWS commits $1B toward new unit

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies...

11d ago

AZN

BMY

Anthropic takes aim at pharma industry with Claude Science, STAT reports

Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a...

11d ago

AZN

BMY

Merck price target raised to $155 from $136 at Scotiabank

Scotiabank raised the firm’s price target on Merck (MRK) to $155 from $136 and keeps an Outperform rating...

11d ago

MRK

Merck’s Lung Cancer Strategy and Next-Gen PD-1/VEGF Pipeline Underpin Buy Rating, $130 Price Target Reiterated

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Merck & Company, retaining the...

1M ago

MRK

Hold Rating Reiterated on Merck as sac-TMT Phase 3 Win Offsets Full Valuation; $125 Price Target Unchanged

Geoff Meacham, an analyst from Citi, maintained the Hold rating on Merck & Company. The associated price target...

1M ago

MRK

Winrevair’s Mixed Phase 2 Signal Leaves Merck’s Risk‑Reward Balanced, Supporting a Hold Rating

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Merck & Company. The associated price...

3M ago

MRK

Merck’s Emerging HIV Franchise: Undervalued Long-Acting Opportunity in a $25B+ Market Supporting a Buy Rating

Analyst Asad Haider of Goldman Sachs maintained a Buy rating on Merck & Company, boosting the price target...

4M ago

MRK

MRK FAQ

What was Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s price range in the past 12 months?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S lowest stock price was C$23.61 and its highest was C$30.21 in the past 12 months.

What is Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s market cap?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s market cap is C$437.85B.

When is Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s upcoming earnings report date?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s upcoming earnings report date is Aug 04, 2026 which is in 24 days.

How were Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s earnings last quarter?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S released its earnings results on Apr 30, 2026. The company reported -C$2.353 earnings per share for the quarter, missing the consensus estimate of N/A by -C$2.353.

Is Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S overvalued?

According to Wall Street analysts Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S pay dividends?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S does not currently pay dividends.

What is Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s EPS estimate?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S have?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S has 2,469,824,500 shares outstanding.

What happened to Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s price movement after its last earnings report?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S reported an EPS of -C$2.353 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.45%.

Which hedge fund is a major shareholder of Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S?

Currently, no hedge funds are holding shares in TSE:MRK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology